Kenvue (NYSE:KVUE) Stock Price Down 5.5% - What's Next?

Kenvue Inc. (NYSE:KVUE - Get Free Report) shares were down 5.5% on Tuesday . The stock traded as low as $22.31 and last traded at $22.37. Approximately 6,581,931 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 16,285,860 shares. The stock had previously closed at $23.67.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Barclays upped their price target on shares of Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research note on Monday, May 12th. Evercore ISI started coverage on shares of Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price on the stock. Piper Sandler raised their price target on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. UBS Group lifted their price target on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Friday, May 9th. Finally, Citigroup increased their price target on shares of Kenvue from $22.00 to $24.50 and gave the stock a "neutral" rating in a report on Friday, May 9th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Kenvue has an average rating of "Hold" and a consensus price target of $25.33.

Kenvue Stock Down 2.4%

The company has a market cap of $41.58 billion, a P/E ratio of 40.89, a P/E/G ratio of 2.62 and a beta of 1.02. The stock has a 50-day moving average of $23.25 and a two-hundred day moving average of $22.62. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The firm had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. During the same period in the previous year, the business posted $0.28 EPS. The business's quarterly revenue was down 3.9% on a year-over-year basis. On average, research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were paid a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.78%. Kenvue's dividend payout ratio (DPR) is currently 149.09%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. LaFleur & Godfrey LLC increased its holdings in Kenvue by 29.8% during the 4th quarter. LaFleur & Godfrey LLC now owns 81,300 shares of the company's stock valued at $1,736,000 after purchasing an additional 18,650 shares during the period. Caprock Group LLC boosted its holdings in Kenvue by 29.0% in the fourth quarter. Caprock Group LLC now owns 45,382 shares of the company's stock worth $969,000 after acquiring an additional 10,191 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. grew its position in Kenvue by 5.6% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 57,578 shares of the company's stock valued at $1,229,000 after purchasing an additional 3,028 shares during the last quarter. Spire Wealth Management purchased a new position in Kenvue in the 4th quarter worth approximately $95,000. Finally, U.S. Capital Wealth Advisors LLC raised its stake in shares of Kenvue by 5.6% in the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 29,298 shares of the company's stock worth $626,000 after purchasing an additional 1,551 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.